In a report released yesterday, Richard Anderson from Mizuho Securities reiterated a Buy rating on Sabra Healthcare REIT (NASDAQ: SBRA), with a price target of $26. The company’s shares closed on Friday at $22.08.
According to TipRanks.com, Anderson is a 4-star analyst with an average return of 5.6% and a 67.6% success rate. Anderson covers the Financial sector, focusing on stocks such as Apartment Investment & Management, Hudson Pacific Properties, and National Health Investors.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sabra Healthcare REIT with a $23.75 average price target, implying a 7.6% upside from current levels. In a report issued on August 9, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $25 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.79 and a one-year low of $15.78. Currently, Sabra Healthcare REIT has an average volume of 1.37M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sabra Health Care REIT, Inc. engages in managing and investing in healthcare-related real estate properties. It focuses on the acquisition, financing, and owning real estate property to be leased to third party tenants in the healthcare sector. The company was founded on May 10, 2010 and is headquartered in Irvine, CA.
